Communiqués HUTCHMED (China) Limited

Actions

HCM

KYG4672N1198

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:04 13/06/2025			Varia. 5j.	Varia. 1 janv.
252,00 ^GBX	-4,18%		+12,00%	+7,23%

09/06	HUTCHMED Limited Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:40 PM
05/06	Le médicament combiné contre le cancer du rein d'Hutchmed et d'Innovent accepté pour examen en Chine	MT

Communiqués

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025	24/04	AQ
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China	22/04	AQ
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK for the Treatment of Relapsed or Refractory Follicular Lymphoma	24/03	AQ
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025	20/03	AQ
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China	06/03	AQ
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	14/01	AQ
HUTCHMED China : Announces US$608 million Divestment of Non Core Joint Venture Form 6 K	02/01	PU
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy	02/01	AQ
HUTCHMED China : to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) Form 6 K	13/12	PU
HUTCHMED China : Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy Form 6 K	12/12	PU
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy	12/12	AQ
HUTCHMED China : and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Form 6 K	03/12	PU
HUTCHMED China : Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms Form 6 K	29/11	PU
HUTCHMED China : Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan Form 6 K	22/11	PU
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan	22/11	AQ
HUTCHMED China : Announces Appointment of Independent Non executive Director and Member of Board Committee Form 6 K	20/11	PU
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	20/11	AQ
HUTCHMED China : Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress Form 6 K	06/11	PU
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress	06/11	AQ
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda	31/10/24	AQ
HUTCHMED China : Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial Form 6 K	16/10/24	PU
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial	16/10/24	AQ
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer	09/09/24	AQ
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China	02/09/24	AQ
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia	21/08/24	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués HUTCHMED (China) Limited

Actions

HCM

KYG4672N1198

Produits pharmaceutiques

Communiqués

Filtres